GSK 'Avandia' which disappeared from the market with the reason of cardiovascular safety controversy in 2011, will soon be re-released
Medical community is expecting that GSK 'Avandia' which disappeared from the market with the reason of cardiovascular safety controversy in 2011, will soon be re-released. Because last November which is 2 year after the safety controversy, the U.S. FDA gave indulgence to 'Avandia' that it does no...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
